Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

被引：0
|
作者：
Fizazi, K. [1 ]
Shore, N. [2 ]
Smith, M. [3 ]
Carles, J. [4 ]
Lebret, T. [5 ]
Lietuvietis, V. [6 ]
Mahammedi, H. [7 ]
Rannikko, A. [8 ]
Vjaters, E. [9 ]
Werbrouck, P. [10 ]
Miskic, M. [11 ]
Kuss, I. [12 ]
Le Berre, M. [13 ]
Borghesi, G. [14 ]
Sarapohja, T. [15 ]
Fayerabend, S. [16 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Paris, France
[2] Carolina Urol Res Ctr, Atlant Urol Clin, Myrtle Beach, SC USA
[3] Massachusetts Gen Hosp, Genitourinary Canc Ctr, Boston, MA 02114 USA
[4] Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
[5] Hosp FOCH, Dept Urol & Renal Transplantat, Suresnes, France
[6] Riga Eastern Clin Univ Hosp, Urol Clin, Riga, Latvia
[7] Jean Perrin Ctr, Dept Med Oncol, Clermont Ferrand, France
[8] Helsinki Univ Hosp Comprehens Canc Ctr, Dept Urol, Helsinki, Finland
[9] P Stradins Clin Univ Hosp, Urol Ctr, Riga, Latvia
[10] AZ Groeninge, Urol Ctr, Kortrijk, Belgium
[11] Bayer Consumer Care AG, Dept Oncol, Basel, Switzerland
[12] Bayer AG, Dept Clin Dev Oncol, Berlin, Germany
[13] Bayer Healthcare SAS, Dept Clin Stat, Loos, France
[14] Bayer AG, Dept TA Oncol, Berlin, Germany
[15] Orion Corp, Orion Pharma, Espoo, Finland
[16] Studienpraxis Urol, Dept Urooncol, Nuertigen, Germany
来源：
EUROPEAN UROLOGY | 2021年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P1226
引用
收藏
页码：S1740 / S1741
页数：2
相关论文
共 50 条
  • [21] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
    Fizazi, K.
    Shore, N. D.
    Tammela, T. L. J.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Petrenciuc, O.
    Snapir, A.
    Sarapohja, T.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S1328 - S1328
  • [22] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
    Boegemann, M.
    Fizazi, K.
    Shore, N.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M. -A.
    Petrenciuc, O.
    Snapir, A.
    Sarapohja, T.
    Smith, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 225 - 225
  • [23] Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.
    Small, Eric Jay
    Saad, Fred
    Rathkopf, Dana E.
    Hadaschik, Boris A.
    Chowdhury, Simon
    Yu, Margaret K.
    Lopez-Gitlitz, Angela
    Rooney, Oliver Brendan
    Shu, Youyi
    Darif, Mohamed
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
    Fizazi, Karim
    Shore, Neal D.
    Smith, Matthew Raymond
    Ramos, Rodrigo
    Jones, Robert J.
    Niegisch, Guenter
    Vjaters, Egils
    Ortiz, Jorge A.
    Liang, Steve
    Wang, Yuan
    Srinivasan, Shankar
    Sarapohja, Toni
    Verholen, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Apalutamide (APA) and Overall Survival (OS) in Patients (PTS) with Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC): Updated Results from The Phase 3 Spartan Study
    Hadaschik, Boris A.
    Smith, Matthew R.
    Saad, Fred
    Chowdhury, Simon
    Oudards, Stephane
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    De Porre, Peter
    Smith, Andressa
    Zhang, Ke
    Lopez-Gitlitz, Angela
    Small, Eric J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 71 - 71
  • [26] Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
    Smith, Matthew R.
    Thomas, Shibu
    Chowdhury, Simon
    Olmos, David
    Li, Jinhui
    Mainwaring, Paul N.
    Oudard, Stephane
    Feng, Felix Y.
    Gormley, Michael
    Ricci, Deborah S.
    Rooney, Brendan
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Small, Eric J.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Prespecified interim analysis of the DARolutamide ObservationaL (DAROL) study in Black/African American patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Yu, Evan Y.
    Pieczonka, Christopher
    Suzuki, Hiroyoshi
    Briganti, Alberto
    Luz, Murilo
    Murphy, Declan
    Adorjan, Patrick
    Ghadessi, Mercedeh
    Verholen, Frank
    Armstrong, Andrew J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [28] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study
    Feng, Felix
    Thomas, Shibu
    Gormley, Michael
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Cheng, Shinta
    Ricci, Deborah S.
    Rooney, Brendan
    Mainwaring, Paul N.
    Olmos, David
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris
    Fishbane, Nick
    Davicioni, Elai
    Liu, Yang
    Small, Eric J.
    Smith, Matthew R.
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Uemura, Hiroji
    Matsushima, Hisashi
    Kobayashi, Kazuki
    Mizusawa, Hiroya
    Nishimatsu, Hiroaki
    Fizazi, Karim
    Smith, Matthew
    Shore, Neal
    Tammela, Teuvo
    Tabata, Ken-ichi
    Matsubara, Nobuaki
    Iinuma, Masahiro
    Uemura, Hirotsugu
    Oya, Mototsugu
    Momma, Tetsuo
    Kawakita, Mutsushi
    Fukasawa, Satoshi
    Kobayashi, Tadahiro
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Suzuki, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 578 - 590
  • [30] Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation
    Mainwaring, P.
    Small, E.
    Uemura, H.
    Lee, J. Y.
    Pang, S-T.
    Marx, G.
    Kwon, T. G.
    Satoh, T.
    Bhaumik, A.
    Cheng, S.
    Londhe, A.
    Lopez-Gitlitz, A.
    Smith, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 68 - 68
12345